Quest for Novel Preventive and Therapeutic Options Against Multidrug-Resistant Pseudomonas aeruginosa
Sidra Irum1, Saadia Andleeb1, Amjad Ali1
1Department of Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Science & Technology (NUST), Sector H-12, Islamabad, 44000 Pakistan.
Abstract:
Pseudomonas aeruginosa (P. aeruginosa) is a critical healthcare challenge due to its ability to cause persistent infections and the acquisition of antibiotic resistance mechanisms. Lack of preventive vaccines and rampant drug resistance phenomenon has rendered patients vulnerable. As new antimicrobials are in the preclinical stages of development, mining for the unexploited drug targets is also crucial. In the present study, we designed a B- and T-cell multi-epitope vaccine against P. aeruginosa using a subtractive proteomics and immunoinformatics approach. A total of five proteins were shortlisted based on essentiality, extracellular localization, virulence, antigenicity, pathway association, hydrophilicity, and low molecular weight. These include two outer membrane porins; OprF (P13794) and OprD (P32722), a protein activator precursor pra (G3XDA9), a probable outer membrane protein precursor PA1288 (Q9I456), and a conserved hypothetical protein PA4874 (Q9HUT9). These shortlisted proteins were further analyzed to identify immunogenic and antigenic B- and T-cell epitopes. The best scoring epitopes were then further subjected to the construction of a polypeptide multi-epitope vaccine and joined with cholera toxin B subunit adjuvant. The final chimeric construct was docked with TLR4 and confirmed by normal mode simulation studies. The designed B- and T-cell multi-epitope vaccine candidate is predicted immunogenic in nature and has shown strong interactions with TLR-4. Immune simulation predicted high-level production of B- and T-cell population and maximal expression was ensured in E. coli strain K12. The identified drug targets qualifying the screening criteria were: UDP-2-acetamido-2-deoxy-d-glucuronic acid 3-dehydrogenase WbpB (G3XD23), aspartate semialdehyde dehydrogenase (Q51344), 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase (Q9HV71), 3-deoxy-D-manno-octulosonic-acid transferase (Q9HUH7), glycyl-tRNA synthetase alpha chain (Q9I7B7), riboflavin kinase/FAD synthase (Q9HVM3), aconitate hydratase 2 (Q9I2V5), probable glycosyltransferase WbpH (G3XD85) and UDP-3-O-[3-hydroxylauroyl] glucosamine N-acyltransferase (Q9HXY6). For druggability and pocketome analysis crystal and homology structures of these proteins were retrieved and developed. A sequence-based search was performed in different databases (ChEMBL, Drug Bank, PubChem and Pseudomonas database) for the availability of reported ligands and tested drugs for the screened targets. These predicted targets may provide a basis for the development of reliable antibacterial preventive and therapeutic options against P. aeruginosa.
Supplementary Information:
The online version contains supplementary material available at 10.1007/s10989-021-10255-3.
Insights
This study designed a novel multi-epitope vaccine and identified new drug targets against Pseudomonas aeruginosa, a major healthcare threat. The vaccine candidate shows promise for preventing persistent infections and combating antibiotic resistance.
Area of Science:
- Infectious Diseases
- Vaccinology
- Drug Discovery
- Computational Biology
Background:
- Pseudomonas aeruginosa (P. aeruginosa) poses a significant healthcare challenge due to persistent infections and widespread antibiotic resistance.
- Existing preventive vaccines are lacking, and drug resistance necessitates the exploration of novel therapeutic strategies and drug targets.
Purpose of the Study:
- To design a multi-epitope vaccine targeting both B- and T-cells against P. aeruginosa.
- To identify and validate novel drug targets for developing new antibacterial agents against P. aeruginosa.
Main Methods:
- A subtractive proteomics and immunoinformatics approach was employed to identify essential, extracellular, and antigenic proteins.
- Immunogenic B- and T-cell epitopes were identified from shortlisted proteins and assembled into a multi-epitope vaccine construct with a cholera toxin B subunit adjuvant.
- In silico docking with TLR4, normal mode simulations, and druggability analyses of identified targets were performed.
Main Results:
- A multi-epitope vaccine candidate was designed, predicted to be immunogenic and interact strongly with TLR-4.
- Immune simulations indicated high B- and T-cell population production.
- Nine potential drug targets were identified, with preliminary druggability and pocketome analyses completed.
Conclusions:
- The designed multi-epitope vaccine candidate shows potential for preventing P. aeruginosa infections.
- The identified drug targets offer a foundation for developing new preventive and therapeutic options against P. aeruginosa.
More Related Videos
06:42Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance
Published on: September 27, 2024
11:35Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
Published on: May 4, 2018
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Hand hygiene
Hand washing...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
